GSK plc with ticker (LON:GSK) now has a potential upside of 8.2% according to Barclays.
Barclays set a target price of 1,575 GBX for the company, which when compared to the GSK plc share price of 1,456 GBX at opening today (29/12/2023) indicates a potential upside of 8.2%. Trading has ranged between 1,303 (52 week low) and 1,726 (52 week high) with an average of 5,635,002 shares exchanging hands daily. The market capitalisation at the time of writing is £60,252,486,880.
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
GSK plc 8.2% potential upside indicated by Barclays
- Written by: Charlotte Edwards
Latest Company News
GSK announced European Commission approval of Exdensur (depemokimab) as an add-on treatment for severe asthma with type 2 inflammation in patients aged 12 and older, and for adults with severe chronic rhinosinusitis with nasal polyps.
GSK plc announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterised by raised blood eosinophils.
GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines across Respiratory, Immunology & Inflammation, Oncology and HIV.
GSK plc announced that the European Commission has approved its RSV vaccine, Arexvy, for use in adults aged 18 years and older.
GSK has received European Commission approval for a prefilled syringe presentation of its Shingrix shingles vaccine.
GSK plc has announced that China’s National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD characterised by raised blood eosinophils.
